Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.90 USD
-0.10 (-3.33%)
Updated Nov 5, 2024 10:30 AM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALLO 2.90 -0.10(-3.33%)
Will ALLO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALLO
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Other News for ALLO
Vanguard Group Inc's Strategic Acquisition in Allogene Therapeutics Inc
Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
Strong Buy Rating for Allogene Therapeutics Amidst Promising Clinical Data and Favorable Valuation
Allogene receives FDA RMAT designation for its metastatic renal cell carcinoma treatment